Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 25000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Down 50.0 %
The stock’s 50 day moving average is C$0.01 and its 200 day moving average is C$0.01. The company has a market capitalization of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02. The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- What is the S&P 500 and How It is Distinct from Other Indexes
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- What Investors Need to Know to Beat the Market
- Top 3 Beverage Stocks Pouring Out Profits
- What Are Dividend Champions? How to Invest in the Champions
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
